OXFORD BIOMEDICA (UK) LIMITED and SYNCOPATION LIFE SCIENCES INC LICENCE AND SUPPLY AGREEMENTLicence and Supply Agreement • November 6th, 2023 • CARGO Therapeutics, Inc. • Biological products, (no disgnostic substances) • England and Wales
Contract Type FiledNovember 6th, 2023 Company Industry Jurisdiction
Akers Biosciences, Inc.Licence and Supply Agreement • August 7th, 2013 • Akers Biosciences Inc
Contract Type FiledAugust 7th, 2013 Company
LICENCE AND SUPPLY AGREEMENT betweenLicence and Supply Agreement • January 24th, 2005 • Gentium S.p.A.
Contract Type FiledJanuary 24th, 2005 Company(Fiscal Code and Vat Code No. 02098100130), with legal offices in Italy at Plazza XX Settembre, no2, 22079 Villa Guardia (CO), acting through its Legal Representative Ms. Laura Iris Ferro, born in Milan on August 3rd, 1951, and domiciled for his office for the purposes of this agreement care of the offices of the Company (hereinafter referred to as "GENTIUM")
ANDLicence and Supply Agreement • March 21st, 2003 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • New York
Contract Type FiledMarch 21st, 2003 Company Industry Jurisdiction
EXECUTION COPY London/090/075921-00001/RBF/MEXG: L_LIVE_EMEA1:13015405v3Licence and Supply Agreement • October 8th, 2013 • Akers Biosciences Inc • In vitro & in vivo diagnostic substances • England and Wales
Contract Type FiledOctober 8th, 2013 Company Industry Jurisdiction
Cabaletta Bio, Inc. 2929 Arch Street, Suite 600, Philadelphia, PA 19104, USA Attention: CEO To whom it may concern Amendment to Licence and Supply AgreementLicence and Supply Agreement • August 10th, 2023 • Cabaletta Bio, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledAugust 10th, 2023 Company Industry
Date: 26 June 2003 ELAN CORPORATION, PLC. AND WATSON LABORATORIES, INC. AMENDED AND RESTATED LICENCE AND SUPPLY AGREEMENT (VERAPAMIL)Licence and Supply Agreement • August 14th, 2015 • Recro Pharma, Inc. • Pharmaceutical preparations • New York
Contract Type FiledAugust 14th, 2015 Company Industry JurisdictionIn the event that Elan acquires or merges with a third party entity, Elan Know-How shall not include any know-how to the extent that such know-how relates to a product containing the same active ingredient as the DSDF which has been approved for marketing or is in development by the said third party entity at the time of such acquisition or merger. For the avoidance of doubt, the occurrence of any such acquisition or merger shall not affect the license of the Elan Know-How granted to Watson hereunder.